Anti-Mllerian Hormone in women with polycystic ovary syndrome before and after therapy with metformin

Hormone and Metabolic Research

Volumn 43, Issue 10, 2011, Pages 723-727

  Tomova, A ^a   Deepinder, F ^b   Robeva, R ^a   Kirilov, G ^a   Mechandjiev, Z ^a   Kumanov, P ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anti Mllerian hormone; hyperandrogenism; hyperinsulinism; polycystic ovary syndrome; testosterone

Indexed keywords

GLUCOSE; INSULIN; LIPID; METFORMIN; MUELLERIAN INHIBITING FACTOR; SEX HORMONE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY FAT; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; MENSTRUAL CYCLE; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; WAIST CIRCUMFERENCE; ADOLESCENT; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL;

ADOLESCENT; ADULT; ANTI-MULLERIAN HORMONE; CASE-CONTROL STUDIES; FEMALE; HUMANS; METFORMIN; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 80052962751     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1286307     Document Type: Article

References (28)

1. Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, Ninfa EG, Frey AZ, Gash DJ, Chow EP. Isolation of the bovine and human genes for Mllerian inhibiting substance and expression of the human gene in animal cells. Cell: 1986; 45 685 698 (Pubitemid 16063132)
2. La Marca A, Volpe A. Anti-Mllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol: 2006; 64 603 610 (Pubitemid 43774997)
3. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril: 2002; 77 357 362 (Pubitemid 34083560)
4. Van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, Fauser BJ, Themmen AP, te Velde ER. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril: 2005; 83 979 987
5. Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum mllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril: 2002; 77 41 46
6. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab: 2003; 88 57 62
7. Laven JS, Mulders AG, Visser JA, Themmen AP, de Jong FH, Fauser BC. Anti-Mllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab: 2004; 89 318 323 (Pubitemid 38183899)
8. La Marca A, Orvieto R, Giulini S, Jasonni VM, Volpe A, De Leo V. Mllerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril: 2004; 82 970 972 (Pubitemid 39346455)
9. Pigny P, Jonard S, Robert Y, Dewailly D. Serum Anti-Mllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab: 2006; 91 941 945 (Pubitemid 43357762)
10. Cheang KI, Sharma ST, Nestler JE. Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? Gynecol Endocrinol: 2006; 22 595 604 (Pubitemid 44915725)
11. De Leo V, Musacchio MC, Morgante G, Piomboni P, Petraglia F. Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod: 2006; 21 2252 2256 (Pubitemid 44530597)
12. Kocak I, Ustun C. Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. J Obstet Gynaecol Res: 2006; 32 292 298 (Pubitemid 43800421)
13. Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, Seifer DB. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril: 2005; 83 30 36
14. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Mllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod: 2005; 20 1820 1826 (Pubitemid 40932362)
15. Carlsen SM, Vanky E, Fleming R. Anti-Mulerian hormone concentrations in androgen-supressed women with polycystic ovary syndrome. Hum Reprod: 2009; 24 1732 1738
16. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril: 2004; 81 19 25
17. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab: 1961; 21 1440 1447
18. De Simone M, Verrotti A, Iughetti L, Palumbo M, Farello G, Di Cesare E, Bernabei R, Rosato T, Lozzi S, Criscione S. Increased visceral adipose tissue is associated with increased circulating insulin and decreased sex hormone binding globulin levels in massively obese adolescent girls. J Endocrinol Invest: 2001; 24 438 444 (Pubitemid 32573794)
19. Matthews DR, Hosker JP, Rudenski AS, Navlor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia: 1985; 28 412 419 (Pubitemid 15018832)
20. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab: 1999; 84 3666 3672 (Pubitemid 30645223)
21. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab: 2005; 90 4650 4658 (Pubitemid 41159355)
22. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev: 1997; 18 774 800 (Pubitemid 28009567)
23. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev: 1999; 20 535 582 (Pubitemid 30647079)
24. Escobar-Morreale HF, Roldan B, Barrio R, Alonso M, Sancho J, de la Calle H, Garca-Robles R. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab: 2000; 85 4182 4187 (Pubitemid 32055370)
25. Chen MJ, Yang WS, Chen CL, Wu MY, Yang YS, Ho HN. The relationship between anti-Mllerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod: 2008; 23 952 957
26. Palomba S, Falbo A, Orio F Jr, Tolino A, Zullo F. Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome. Fertil Steril: 2009; 91 2557 2567
27. Maciel GA, Soares Jnior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril: 2004; 81 355 360 (Pubitemid 38223916)
28. Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab: 2005; 90 4593 4598 (Pubitemid 41159348)